ARTICLE | Company News
Neurogen, Aventis CRF1 deal
December 20, 2001 8:00 AM UTC
AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1) antagonist compounds, for use in treating depression, anxiety and other stress-related disorders, including le...